Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 16/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.78 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11915751 | 0.96 | SLC22A12 (0.71) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL19987624 | 0.91 | SLC22A12 (0.79) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL4735395 | 0.91 | SLC22A12 (0.70) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL4736112 | 0.90 | SLC22A12 (0.75) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL21164758 | 0.90 | SLC22A12 (0.69) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL13445169 | 0.90 | SLC22A12 (0.78) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL4736210 | 0.89 | SLC22A12 (0.74) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL28666334 | 0.89 | SLC22A12 (0.61) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL4735350 | 0.89 | SLC22A12 (0.82) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL16310802 | 0.88 | SLC22A12 (0.78) | SLC22A12CYP2C19CYP2C9CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116500-B | Purification method of Resinard key intermediate | 北京鑫开元医药科技有限公司海南分公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-111116501-B | Synthesis method of Ravinard intermediate capable of effectively reducing impurity content | 北京鑫开元医药科技有限公司海南分公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-111116501-B | Synthesis method of Ravinard intermediate capable of effectively reducing impurity content | 北京鑫开元医药科技有限公司海南分公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3279188-B1 | AXIALLY CHIRAL ISOMERS, AND PREPARATION METHODS THEREFOR AND PHARMACEUTICAL USES THEREOF | MEDSHINE DISCOVERY INC (CN) | 2020-09-09 | — | — | EP | disclosed |
| CN-107955029-B | Preparation method of Raschindde | 成都美域高制药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111220728-A | Detection method for effectively separating Raschindyleigh and main impurities | 北京鑫开元医药科技有限公司海南分公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-111116500-A | Purification method of Resinard key intermediate | 北京鑫开元医药科技有限公司海南分公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116501-A | Synthesis method of Ravinard intermediate capable of effectively reducing impurity content | 北京鑫开元医药科技有限公司海南分公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116501-A | Synthesis method of Ravinard intermediate capable of effectively reducing impurity content | 北京鑫开元医药科技有限公司海南分公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2135608-A1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135608-A1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009070740-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C19 1898/4885CYP2C9 1309/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885CYP2C19 1696/4885CYP2C9 1526/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SLC22A12 1536/4885CYP2C19 660/4885CYP2C9 381/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | SLC22A12 1095/4885CYP2C19 1898/4885CYP2C9 1309/4885 |
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | TXNRD3, TXNRD1, CBR3 | SLC22A12 2314/4885CYP2C19 992/4885CYP2C9 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.